Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Disease Modifying ◽

OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate

10.1136/annrheumdis-2018-eular.4237 ◽

2018 ◽

Cited By ~ 3

Author(s):

J. Smolen ◽

S. Cohen ◽

P. Emery ◽

W. Rigby ◽

Y. Tanaka ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Blind Study ◽

Double Blind Study ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(18)31115-2 ◽

2018 ◽

Vol 391 (10139) ◽

pp. 2503-2512 ◽

Cited By ~ 114

Author(s):

Gerd R Burmester ◽

Joel M Kremer ◽

Filip Van den Bosch ◽

Alan Kivitz ◽

Louis Bessette ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Disease Modifying

086 Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs

Rheumatology ◽

10.1093/rheumatology/kez106.085 ◽

2019 ◽

Vol 58 (Supplement_3) ◽

Author(s):

David Walker ◽

Mark C Genovese ◽

Kenneth Kalunian ◽

Jacques-Eric Gottenberg ◽

Kurt de Vlam ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Inadequate Response ◽

Phase 3 ◽

Safety And Efficacy ◽

Disease Modifying

060 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate

Rheumatology ◽

10.1093/rheumatology/kez106.059 ◽

2019 ◽

Vol 58 (Supplement_3) ◽

Cited By ~ 1

Author(s):

J S Smolen ◽

S Cohen ◽

P Emery ◽

W Rigby ◽

Y Tanaka ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Blind Study ◽

Double Blind Study ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1164186.624873 ◽

2009 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Jak Inhibitor ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo

Faculty Opinions recommendation of Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727328077.793564275 ◽

2019 ◽

Author(s):

Ladislav Senolt

Keyword(s):

Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

Safety and efficacy of agomelatine in combination with psychosocial counselling in children and adolescents with major depressive disorder: a double-blind, randomised, controlled, phase 3 trial in nine countries

The Lancet Psychiatry ◽

10.1016/s2215-0366(21)00390-4 ◽

2021 ◽

Author(s):

Celso Arango ◽

Jan K Buitelaar ◽

Jörg M Fegert ◽

Valérie Olivier ◽

Pierre-François Pénélaud ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Children And Adolescents ◽

Major Depressive ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Psychosocial Counselling ◽

SAT0145 Efficacy and Safety of Sirukumab in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of A Randomized, Double-Blind, Placebo-Controlled Study: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.3741 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 717.1-717

Author(s):

T. Takeuchi ◽

C. Thorne ◽

G. Karpouzas ◽

S. Sheng ◽

W. Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Drug Treatment ◽

Controlled Study ◽

Efficacy And Safety ◽

Treatment Results ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

THU0202 Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.730 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A232.1-A232 ◽

Cited By ~ 2

Author(s):

J. S. Smolen ◽

J. Kay ◽

R. Landewé ◽

E. L. Matteson ◽

N. Gaylis ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase 3 ◽

Safety And Efficacy ◽

Final Study ◽

Study Results ◽

Factor Therapy ◽

Necrosis Factor